13-Jan-2025 6:00 AM CST - Business Wire Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. Fourth quarter 2024 preliminary unaudited financial results For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of approximately $200 million, an increase of 29% Reported approximately 57,300 oncology clinical tests (excluding Shield
2-Jan-2025 3:05 PM CST - Business Wire Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Guardant Healths management is scheduled to present and participate in a Q&A session on Monday, January 13, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. Interested parties may access live and archived webcasts of the sessions on the Investors section
6-Nov-2024 3:05 PM CST - Business Wire Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Recorded revenue of $191.5 million for the third quarter of 2024, an increase of 34% over the third quarter of 2023 Reported 53,100 clinical tests (excluding Shield) and 10,500 biopharma tests in the third quarter of 2024, representing increases of 21% and 40%, respectively
15-Oct-2024 3:05 PM CST - Business Wire Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investors section of the company website at: www.guardanthealth.com. The webcast wi
13-Jan-2025 6:00 AM CST - Business Wire Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. Fourth quarter 2024 preliminary unaudited financial results For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of approximately $200 million, an increase of 29% Reported approximately 57,300 oncology clinical tests (excluding Shield
2-Jan-2025 3:05 PM CST - Business Wire Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Guardant Healths management is scheduled to present and participate in a Q&A session on Monday, January 13, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. Interested parties may access live and archived webcasts of the sessions on the Investors section
6-Nov-2024 3:05 PM CST - Business Wire Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Recorded revenue of $191.5 million for the third quarter of 2024, an increase of 34% over the third quarter of 2023 Reported 53,100 clinical tests (excluding Shield) and 10,500 biopharma tests in the third quarter of 2024, representing increases of 21% and 40%, respectively
15-Oct-2024 3:05 PM CST - Business Wire Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investors section of the company website at: www.guardanthealth.com. The webcast wi
